|
| U.S. Brand
Names |
|
| Naftin® |

|
|
| Generic
Available |
|
|
No |

|
|
| Synonyms |
|
|
Naftifine Hydrochloride |

|
|
| Pharmacological Index |
|
|
Antifungal Agent, Topical |

|
|
| Use |
|
|
Topical treatment of tinea cruris (jock itch), tinea corporis (ringworm), and
tinea pedis (athlete's foot) |

|
|
| Pregnancy Risk
Factor |
|
|
B |

|
|
| Contraindications |
|
|
Hypersensitivity to any component |

|
|
| Warnings/Precautions |
|
|
For external use only |

|
|
| Adverse
Reactions |
|
|
>10%: Local: Burning, stinging
1% to 10%:
Dermatologic: Erythema, itching
Local: Dryness, irritation |

|
|
| Drug
Interactions |
|
|
No data reported |

|
|
| Mechanism of
Action |
|
|
Synthetic, broad-spectrum antifungal agent in the allylamine class; appears
to have both fungistatic and fungicidal activity. Exhibits antifungal activity
by selectively inhibiting the enzyme squalene epoxidase in a dose-dependent
manner which results in the primary sterol, ergosterol, within the fungal
membrane not being synthesized. |

|
|
| Pharmacodynamics/Kinetics |
|
|
Absorption: Systemic, 6% for cream, less than or equal to 4% for gel
Half-life: 2-3 days
Elimination: Metabolites excreted in urine and feces |

|
|
| Usual Dosage |
|
|
Adults: Topical: Apply cream once daily and gel twice daily (morning and
evening) for up to 4 weeks |

|
|
| Mental Health: Effects
on Mental Status |
|
|
None noted |

|
|
| Mental Health:
Effects on Psychiatric
Treatment |
|
|
None noted |

|
|
| Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
|
No information available to require special precautions |

|
|
| Dental Health:
Effects on Dental Treatment |
|
|
No effects or complications reported |

|
|
| Patient
Information |
|
|
External use only; avoid eyes, mouth, and other mucous membranes; do not use
occlusive dressings unless directed to do so; discontinue if irritation or
sensitivity develops; wash hands after application |

|
|
| Nursing
Implications |
|
|
External use only; avoid eyes, mouth, and other mucous membranes; do not use
occlusive dressings unless directed to do so; discontinue if irritation or
sensitivity develops; wash hands after application |

|
|
| Dosage Forms |
|
|
Cream, as hydrochloride: 1% (15 g, 30 g, 60 g)
Gel, topical, as hydrochloride: 1% (20 g, 40 g, 60 g)
|

|
|
Copyright © 2007 Drugs Area
|